Business
Media
Conferences
Publications
CME/CE
Resources
Subscribe

Opinion|Videos|March 4, 2024

An Overview of the SPOTLIGHT Trial for PSMA PET in Prostate Cancer

Author(s)Brian Helfand, MD, PhD, Brian Chapin, MD, Sean P. Collins, MD, PhD

A panel of experts introduce the SPOTLIGHT study, evaluating PSMA PET in patients with prostate cancer.

Episodes in this series

EP. 1 The Evolution of Imaging Techniques in Prostate Cancer

EP. 1 The Evolution of Imaging Techniques in Prostate Cancer

EP. 2 The Utility of PSMA PET in Prostate Cancer

EP. 2 The Utility of PSMA PET in Prostate Cancer

EP. 3 Clinical Development of PSMA-Targeted Therapies

EP. 3 Clinical Development of PSMA-Targeted Therapies

EP. 4 Clinical Practices of PSMA-Targeted Agents in Prostate Cancer

EP. 4 Clinical Practices of PSMA-Targeted Agents in Prostate Cancer

EP. 5 Multidisciplinary Approaches in PSMA PET for Prostate Cancer

EP. 5 Multidisciplinary Approaches in PSMA PET for Prostate Cancer

EP. 6 Patient Profile 1: A 51-Year-Old Man with High-Risk Localized Prostate Cancer

EP. 7 PSMA PET Imaging and Clinical Perspectives from Patient Profile 1

EP. 8 LIGHTHOUSE Trial and The Role of 18F-rhPSMA-7.3 for Staging of Prostate Cancer

EP. 8 LIGHTHOUSE Trial and The Role of 18F-rhPSMA-7.3 for Staging of Prostate Cancer

EP. 9 An Overview of the SPOTLIGHT Trial for PSMA PET in Prostate Cancer

EP. 9 An Overview of the SPOTLIGHT Trial for PSMA PET in Prostate Cancer

EP. 10 SPOTLIGHT Trial and 18F-rhPSMA-7.3 for Prostate Cancer

EP. 10 SPOTLIGHT Trial and 18F-rhPSMA-7.3 for Prostate Cancer

EP. 11 Patient Profile 2: A 62-Year-Old Man with Recurrent Prostate Cancer

EP. 12 Patient Profile 3: A 67-Year-Old Male with Recurrent Prostate Cancer

EP. 13 Future Horizons in PSMA-Targeted Imaging and the Management of Prostate Cancer

EP. 13 Future Horizons in PSMA-Targeted Imaging and the Management of Prostate Cancer

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Content

Annual ACS NCDB report details national trends in prostate cancer care

ByHannah Clarke

January 27th 2026

Pearls & Perspectives: Leadership and Prostate Cancer, with Mark L. Gonzalgo, MD, PhD, MBA

ByAmy M. Pearlman, MD

January 26th 2026

Ridwan I. Alam, MD, MPH, discusses combining PHI and MRI to predict prostate cancer risk

ByRidwan I. Alam, MD, MPH

January 22nd 2026

CaverSTIM device shows initial promise for post-prostatectomy erectile dysfunction

ByHannah Clarke

January 21st 2026

Initial ARID results published in World Journal of Urology as pivotal trial progresses

ByHannah Clarke

January 20th 2026

Latest CME

Breakthroughs in Non–Muscle-Invasive Bladder Cancer: Advancing Patient Care Through Innovation in Treatment

Breakthroughs in Non–Muscle-Invasive Bladder Cancer: Advancing Patient Care Through Innovation in Treatment

February 23, 2026

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

Glenn M. Chertow, MD, MPH; Anil K. Agarwal, MD, FACP, FASN, FNKF, FASDIN; Preethi Yerram, MD

Trending on Urology Times

FDA provides guidance on development pathway for testosterone therapy for women

Treatment Selection in Advanced Prostate Cancer

Annual ACS NCDB report details national trends in prostate cancer care

Advice for the Next Generation of Urologists in mCSPC Management

Strategic Use of ADT in mCSPC From Selection to Escalation